Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2015

01-07-2015 | Research

Identification of Key Genes Associated with Colorectal Cancer Based on the Transcriptional Network

Authors: Guoting Chen, Hengping Li, Xianping Niu, Guofeng Li, Ning Han, Xin Li, Guang Li, Yangzhou Liu, Guixin Sun, Yong Wang, Zengchun Li, Qinchuan Li

Published in: Pathology & Oncology Research | Issue 3/2015

Login to get access

Abstract

Colorectal cancer (CRC) is among the most lethal human cancers, but the mechanism of the cancer is still unclear enough. We aimed to explore the key genes in CRC progression. The gene expression profile (GSE4183) of CRC was obtained from Gene Expression Omnibus database which included 8 normal samples, 15 adenoma samples, 15 CRC samples and 15 inflammatory bowel disease (IBD) samples. Thereinto, 8 normal, 15 adenoma, and 15 CRC samples were chosen for our research. The differentially expressed genes (DEGs) in normal vs. adenoma, normal vs. CRC, and adenoma vs. CRC, were identified using the Wilcoxon test method in R respectively. The interactive network of DEGs was constructed to select the significant modules using the Pearson’s correlation. Meanwhile, transcriptional network of DEGs was also constructed using the g: Profiler. Totally, 2,741 DEGs in normal vs. adenoma, 1,484 DEGs in normal vs. CRC, and 396 DEGs in adenoma vs. CRC were identified. Moreover, function analysis of DEGs in each group showed FcR-mediated phagocytosis pathway in module 1, cardiac muscle contraction pathway in module 6, and Jak-STAT signaling pathway in module 19 were also enriched. Furthermore, MZF1 and AP2 were the transcription factor in module 6, with the target SP1, while SP1 was also a transcription in module 20. DEGs like NCF1, AKT, SP1, AP2, MZF1, and TPM might be used as specific biomarkers in CRC development. Therapy targeting on the functions of these key genes might provide novel perspective for CRC treatment.
Literature
1.
Rebecca SM, Deepa Naishadham MA, Ahmedin Jemal DVM (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30CrossRef
2.
3.
4.
Garagnani P, Pirazzini C, Franceschi C (2013) Colorectal cancer microenvironment: among nutrition, gut microbiota, inflammation and epigenetics. Curr Pharm Des 19:765–778CrossRefPubMed
5.
Vinci S, Gelmini S, Mancini I et al (2013) Genetic and epigenetic factors in regulation of microRNA in colorectal cancers. Methods 59:138–146CrossRefPubMed
6.
Wilkinson J (2012) Epigenome enhancer profiling reveals signature for colon cancer. Epigenomics 4(3):248PubMed
7.
Schweiger MR, Hussong M, Rohr C et al (2013) Genomics and epigenomics of colorectal cancer. Wiley Interdiscip Rev Syst Biol Med 5:205–219CrossRefPubMed
8.
Han Y, Kuang Y, Xue X et al (2014) NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer. Biomed Pharmacother 9:003
9.
Zhang Y, Tian X, Ji H et al. (2014) Expression of SATB1 Promotes the Growth and Metastasis of Colorectal Cancer. PloS one 9
10.
Van Cutsem E, Köhne C-H, Láng I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. JCO 2010(2033):5091
11.
Misale S, Yaeger R, Hobor S et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature
12.
Galamb O, Sipos F, Solymosi N et al (2008) Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results. Cancer Epidemiol Biomarkers Prev 17:2835–2845CrossRefPubMed
13.
Nam S, Park T (2012) Pathway-based evaluation in early onset colorectal cancer suggests focal adhesion and immunosuppression along with Epithelial-Mesenchymal transition. PLoS ONE 7:e31685CrossRefPubMedCentralPubMed
14.
Heijink D, Fehrmann R, de Vries E et al (2011) A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer. Oncogene 30:2026–2036CrossRefPubMed
15.
Barrett T, Troup DB, Wilhite SE et al (2007) NCBI GEO: mining tens of millions of expression profiles—database and tools update. Nucleic Acids Res 35:D760–D765CrossRefPubMedCentralPubMed
16.
Irizarry RA, Hobbs B, Collin F et al (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249–264CrossRefPubMed
17.
Gehan EA (1965) A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:203–223CrossRefPubMed
18.
Adler J, Parmryd I (2010) Quantifying colocalization by correlation: the pearson correlation coefficient is superior to the Mander’s overlap coefficient. J Int Soc Anal Cytol 77:733–742. doi:10.​1002/​cyto.​a.​20896 CrossRef
19.
Collobert R, Bengio S, Mariéthoz J (2002) Torch: a modular machine learning software library. Technical Report IDIAP-RR 02-46, IDIAP
20.
Reimand J, Kull M, Peterson H et al (2007) g: Profiler—a web-based toolset for functional profiling of gene lists from large-scale experiments. Nucleic Acids Res 35:W193–W200CrossRefPubMedCentralPubMed
21.
Alvord G, Roayaei J, Stephens R et al (2007) The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8:R183CrossRefPubMedCentralPubMed
22.
23.
24.
25.
van Spriel AB, van Ojik HH, Bakker A et al (2003) Mac-1 (CD11b/CD18) is crucial for effective Fc receptor–mediated immunity to melanoma. Blood 101:253–258CrossRefPubMed
26.
Roos D, de Boer M, Koker MY et al (2006) Chronic granulomatous disease caused by mutations other than the common GT deletion in NCF1, the gene encoding the p47phox component of the phagocyte NADPH oxidase. Hum Mutat 27:1218–1229CrossRefPubMed
27.
Suraweera N, Zampeli E, Rogers P et al (2004) NCF1 (p47phox) and ncf1 pseudogenes are not associated with inflammatory bowel disease. Inflamm Bowel Dis 10:758–762CrossRefPubMed
28.
Parry D, Squire J (1973) Structural role of tropomyosin in muscle regulation: analysis of the x-ray diffraction patterns from relaxed and contracting muscles. J Mol Biol 75:33–55CrossRefPubMed
29.
Luo YX, Cui J, Wang L et al (2009) Identification of cancer-associated proteins by proteomics and downregulation of beta-tropomyosin expression in colorectal adenoma and cancer. Proteomics Clin Appl 3:1397–1406PubMed
30.
Mlakar V, Berginc G, Volavsek M et al (2009) Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer. BMC Cancer 9:1471–2407
31.
Franke TF, Yang S-I, Chan TO et al (1995) The protein kinase encoded by the < i > Akt</i > proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81:727–736CrossRefPubMed
32.
Baba Y, Nosho K, Shima K et al (2011) Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer 117:1399–1408CrossRefPubMedCentralPubMed
33.
34.
35.
Diaz T, Navarro A, Ferrer G et al (2011) Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS ONE 6:0018856CrossRef
36.
Yue CH, Chiu YW, Tung JN et al (2012) Expression of protein kinase C alpha and the MZF-1 and Elk-1 transcription factors in human breast cancer cells. Chin J Physiol 55:31–36CrossRefPubMed
37.
Hsieh YH, Wu TT, Huang CY et al (2007) Suppression of tumorigenicity of human hepatocellular carcinoma cells by antisense oligonucleotide MZF-1. Chin J Physiol 50:9–15PubMed
38.
Mudduluru G, Vajkoczy P, Allgayer H (2010) Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Mol Cancer Res 8:159–169CrossRefPubMed
39.
Deng Y, Wang J, Wang G et al (2013) p55PIK transcriptionally activated by MZF1 promotes colorectal cancer cell proliferation. Biomed Res Int 868131:23
40.
41.
Kadonaga JT, Carner KR, Masiarz FR et al (1987) Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 51:1079–1090CrossRefPubMed
42.
Lam AK, Chan SS (2014) Leung M Synchronous colorectal cancer: clinical, pathological and molecular implications. World J Gastroenterol 20(22):6815–6820CrossRefPubMedCentralPubMed
43.
Stabach PR, Thiyagarajan MM, Woodfield GW et al (2006) AP2alpha alters the transcriptional activity and stability of p53. Oncogene 25:2148–2159CrossRefPubMed
44.
Banerjee S, Sangwan V, McGinn O et al (2013) Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1. J Biol Chem 288:33927–33938CrossRefPubMedCentralPubMed
45.
Li H, Zhang Y, Strose A et al (2014) Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis. Cell Death Differ 27:69
46.
Zhao Y, Zhang W, Guo Z et al (2013) Inhibition of the transcription factor Sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts. Oncol Rep 30:1782–1792PubMed
Metadata
Title
Identification of Key Genes Associated with Colorectal Cancer Based on the Transcriptional Network
Authors
Guoting Chen
Hengping Li
Xianping Niu
Guofeng Li
Ning Han
Xin Li
Guang Li
Yangzhou Liu
Guixin Sun
Yong Wang
Zengchun Li
Qinchuan Li
Publication date
01-07-2015
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-014-9880-9

Other articles of this Issue 3/2015

Pathology & Oncology Research 3/2015 Go to the issue

Review

The Role of the Mediators of Inflammation in Cancer Development

Research

Lymphadenectomy Should Be Performed Up to the Renal Vein in Patients with Intermediate-High Risk Endometrial Cancer

Research

Functional Variants of Lipid Level Modifier MLXIPL, GCKR, GALNT2, CILP2, ANGPTL3 and TRIB1 Genes in Healthy Roma and Hungarian Populations

Research

A Relation Between Cell Cycle and Intestinal Metaplasia in Oesophageal Biopsies Using Optical and Digital Microscopy

Review

Pathology of Gallbladder Carcinoma: Current Understanding and New Perspectives

Research

HPV-Type Distribution and Reproducibility of Histological Diagnosis in Cervical Neoplasia in Poland
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits